[go: up one dir, main page]

DK1073658T3 - Pyrazolopyrimidinon-cGMP PDE5-inhibitorer til behandling af sexualforstyrrelse - Google Patents

Pyrazolopyrimidinon-cGMP PDE5-inhibitorer til behandling af sexualforstyrrelse

Info

Publication number
DK1073658T3
DK1073658T3 DK99907805T DK99907805T DK1073658T3 DK 1073658 T3 DK1073658 T3 DK 1073658T3 DK 99907805 T DK99907805 T DK 99907805T DK 99907805 T DK99907805 T DK 99907805T DK 1073658 T3 DK1073658 T3 DK 1073658T3
Authority
DK
Denmark
Prior art keywords
treatment
pde5 inhibitors
sexual disorder
cgmp pde5
pyrazolopyrimidinone cgmp
Prior art date
Application number
DK99907805T
Other languages
Danish (da)
English (en)
Inventor
Mark Edward Bunnage
John Paul Mathias
Stephen Derek A Street
Anthony Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9808315.7A external-priority patent/GB9808315D0/en
Priority claimed from GBGB9814187.2A external-priority patent/GB9814187D0/en
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK1073658T3 publication Critical patent/DK1073658T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
DK99907805T 1998-04-20 1999-03-25 Pyrazolopyrimidinon-cGMP PDE5-inhibitorer til behandling af sexualforstyrrelse DK1073658T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9808315.7A GB9808315D0 (en) 1998-04-20 1998-04-20 Therapeutic agents
GBGB9814187.2A GB9814187D0 (en) 1998-06-30 1998-06-30 Therapeutic agents
PCT/IB1999/000519 WO1999054333A1 (fr) 1998-04-20 1999-03-25 Inhibiteurs de cgmp pde5 de pyrazolopyrimidinone servant a traiter le dysfonctionnement sexuel

Publications (1)

Publication Number Publication Date
DK1073658T3 true DK1073658T3 (da) 2003-12-08

Family

ID=26313490

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03013988T DK1371647T3 (da) 1998-04-20 1999-03-25 Pyrazolopyrimidinon-cGMP PDE5-inhibitorer til behandling af sexualforstyrrelse
DK99907805T DK1073658T3 (da) 1998-04-20 1999-03-25 Pyrazolopyrimidinon-cGMP PDE5-inhibitorer til behandling af sexualforstyrrelse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK03013988T DK1371647T3 (da) 1998-04-20 1999-03-25 Pyrazolopyrimidinon-cGMP PDE5-inhibitorer til behandling af sexualforstyrrelse

Country Status (39)

Country Link
US (2) US6251904B1 (fr)
EP (2) EP1371647B1 (fr)
JP (2) JP3721077B2 (fr)
KR (1) KR100449790B1 (fr)
CN (2) CN1134442C (fr)
AP (1) AP1022A (fr)
AR (2) AR015770A1 (fr)
AT (2) ATE247117T1 (fr)
AU (1) AU748352B2 (fr)
BG (1) BG104949A (fr)
BR (1) BR9909808A (fr)
CA (1) CA2329077C (fr)
CO (1) CO5271649A1 (fr)
DE (2) DE69910368T2 (fr)
DK (2) DK1371647T3 (fr)
DZ (1) DZ2773A1 (fr)
EA (1) EA200000969A1 (fr)
ES (2) ES2203078T3 (fr)
GT (1) GT199900053A (fr)
HR (1) HRP20000712A2 (fr)
HU (1) HUP0102543A3 (fr)
ID (1) ID27036A (fr)
IL (2) IL138907A0 (fr)
IS (1) IS5650A (fr)
MA (1) MA26622A1 (fr)
NO (1) NO20005255L (fr)
OA (1) OA11502A (fr)
PA (1) PA8470501A1 (fr)
PE (1) PE20000463A1 (fr)
PL (1) PL343794A1 (fr)
PT (2) PT1371647E (fr)
RS (1) RS50011B (fr)
SI (2) SI1371647T1 (fr)
SK (1) SK15532000A3 (fr)
TN (1) TNSN99073A1 (fr)
TR (1) TR200003039T2 (fr)
TW (1) TW593310B (fr)
UY (1) UY25484A1 (fr)
WO (1) WO1999054333A1 (fr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ299633B6 (cs) 1997-04-25 2008-09-24 Pfizer Inc. Pyrazolopyrimidinony, meziprodukty pro jejich výrobu a farmaceutické a veterinární kompozice na jejich bázi
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
ATE247117T1 (de) 1998-04-20 2003-08-15 Pfizer Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823101D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
US6242444B1 (en) 1999-06-04 2001-06-05 The Jordanian Pharmaceutical Manufacturing And Medical Equipment Co., Ltd. Compounds and pharmaceutical compositions containing the same
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6350751B1 (en) 1999-10-11 2002-02-26 Pfizer Inc. Therapeutic agents
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
JP2003511452A (ja) * 1999-10-11 2003-03-25 ファイザー・インク ホスホジエステラーゼ阻害剤としての５−（２−置換−５−ヘテロシクリルスルホニルピリド−３−イル）−ジヒドロピラゾロ［４，３−ｄ］ピリミジン−７−オン
YU59100A (sh) * 1999-10-11 2003-10-31 Pfizer Inc. Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera
GB9923968D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Therapeutic agents
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
IL139073A0 (en) * 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
GB0000561D0 (en) * 2000-01-11 2000-03-01 Pfizer Ltd Treatment of diabetic ulcers
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
AU2001255849B8 (en) * 2000-04-19 2006-04-27 Lilly Icos, Llc. PDE-V inhibitors for treatment of Parkinson's Disease
US6730786B2 (en) 2000-06-22 2004-05-04 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
US6667398B2 (en) * 2000-06-22 2003-12-23 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
US6420557B1 (en) * 2000-07-28 2002-07-16 Pfizer Inc. Crystalline therapeutic agent
US6809200B2 (en) * 2000-07-28 2004-10-26 Pfizer Inc. Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof
WO2002010171A1 (fr) * 2000-07-28 2002-02-07 Pfizer Limited Agent therapeutique cristallin
EP1176142A1 (fr) * 2000-07-28 2002-01-30 Pfizer Inc. Procédé pour la préparation de pyrazoles
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
GB0025782D0 (en) * 2000-10-20 2000-12-06 Pfizer Ltd Use of inhibitors
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
DE10058663A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Thienopyrimidinen
GB0105893D0 (en) * 2001-03-09 2001-04-25 Pfizer Ltd Pharmaceutically active compounds
US6831074B2 (en) * 2001-03-16 2004-12-14 Pfizer Inc Pharmaceutically active compounds
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US20030073711A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of scleroderma
US6943171B2 (en) 2001-11-09 2005-09-13 Schering Corporation Polycyclic guanine derivative phosphodiesterase V inhibitors
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
ATE478872T1 (de) * 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
PL377657A1 (pl) 2002-12-13 2006-02-06 Warner-Lambert Company Llc Ligand Ó-2-Ű do leczenia dolegliwości dolnych dróg moczowych
DK1620437T3 (da) 2003-04-29 2009-08-24 Pfizer Ltd 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
CN100374441C (zh) * 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
BRPI0506994A (pt) 2004-01-22 2007-07-03 Pfizer derivados de triazol que inibem a atividade antagonista da vasopressina
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7569572B2 (en) 2004-04-07 2009-08-04 Pfizer Inc Pyrazolo[4,3-D]pyrimidines
US20090227562A1 (en) * 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
AU2005277384B2 (en) * 2004-08-17 2011-11-17 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
EP1863795B1 (fr) 2005-03-21 2008-10-29 Pfizer Limited Derives de triazole substitues en tant qu'antagonistes d'oxytocine
EP1879881A2 (fr) * 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibiteurs de la 11-beta hydroxysteroide deshydrogenase de type i
AU2006237300B2 (en) 2005-04-19 2011-10-13 Takeda Gmbh Roflumilast for the treatment of pulmonary hypertension
BRPI0609225A2 (pt) 2005-05-12 2010-03-09 Pfizer formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
EP2258357A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse avec inhibiteur de l'acetylcholinestérase
CA2620333A1 (fr) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenese par modulation du recepteur muscarinique
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (fr) 2006-05-09 2012-02-29 Braincells, Inc. Neurogénèse par modulation d'angiotensine
CA2651862A1 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenese induite par le recepteur 5ht
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US9006258B2 (en) * 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
KR100989093B1 (ko) 2008-01-18 2010-10-25 한화제약주식회사 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물
CN101747282A (zh) 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
EP2379076B1 (fr) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Inhibiteurs de la phosphodiestérase et utilisations de ces derniers
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
MX2010006227A (es) 2010-06-07 2011-12-14 World Trade Imp Exp Wtie Ag Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
WO2013067309A1 (fr) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Procédés et compositions pour l'administration orale de composés agonistes d'un récepteur de la mélanocortine
EP2804603A1 (fr) 2012-01-10 2014-11-26 President and Fellows of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
WO2013109738A1 (fr) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Nouveaux inhibiteurs de la phosphodiestérase et utilisations de ceux-ci
US10899756B2 (en) 2013-07-17 2021-01-26 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
EP3099689B1 (fr) * 2014-01-30 2022-01-26 Council of Scientific and Industrial Research Pyrazolopyrimidinones pour traiter l'impuissance et leur procede de preparation
CN103922960B (zh) * 2014-04-16 2015-10-21 浙江中山化工集团股份有限公司 一种s-异丙甲草胺的合成方法
CN104402811A (zh) * 2014-11-11 2015-03-11 常州大学 一种合成二甲氨基吡啶甲酸的方法
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
UA125650C2 (uk) 2016-09-09 2022-05-11 Інсайт Корпорейшн Регулятори нрk1 на основі похідних піразолопіридину та їх застосування для лікування раку
WO2018049214A1 (fr) 2016-09-09 2018-03-15 Incyte Corporation Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2019051199A1 (fr) 2017-09-08 2019-03-14 Incyte Corporation Composés de 6-cyano-indazole utilisés en tant que modulateurs de kinase 1 progénitrices hématopoïétiques (hpk1)
HRP20220833T1 (hr) 2018-02-20 2022-10-28 Incyte Corporation Derivati n-(fenil)-2-(fenil)pirimidin-4-karboksamida i odgovarajući spojevi kao inhibitori hpk1 za liječenje raka
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
WO2019164847A1 (fr) 2018-02-20 2019-08-29 Incyte Corporation Composés d'indazole et leurs utilisations
SG11202009570SA (en) * 2018-04-06 2020-10-29 Black Belt Tx Ltd Atf6 inhibitors and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
TW202028207A (zh) 2018-09-25 2020-08-01 美商英塞特公司 吡唑并嘧啶化合物及其用途
MX2022001562A (es) 2019-08-06 2022-04-26 Incyte Corp Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1).
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871843A (en) 1983-10-18 1989-10-03 Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions
US4663326A (en) 1985-04-04 1987-05-05 Warner-Lambert Company Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
GB9423910D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
AU708809B2 (en) 1995-03-10 1999-08-12 Sanofi Pharmaceuticals, Inc. 6-aryl pyrazolo{3,4-d}pyrimidin-4-ones and compositions and methods of use thereof
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
CZ299633B6 (cs) * 1997-04-25 2008-09-24 Pfizer Inc. Pyrazolopyrimidinony, meziprodukty pro jejich výrobu a farmaceutické a veterinární kompozice na jejich bázi
ATE247117T1 (de) 1998-04-20 2003-08-15 Pfizer Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
US6087368A (en) 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase

Also Published As

Publication number Publication date
DK1371647T3 (da) 2005-10-17
NO20005255L (no) 2000-12-19
PE20000463A1 (es) 2000-05-26
CO5271649A1 (es) 2003-04-30
EP1371647B1 (fr) 2005-07-13
SK15532000A3 (sk) 2001-12-03
SI1371647T1 (en) 2005-10-31
NO20005255D0 (no) 2000-10-19
BR9909808A (pt) 2000-12-26
PT1371647E (pt) 2005-10-31
AR015770A1 (es) 2001-05-16
PA8470501A1 (es) 2000-09-29
CN1495169A (zh) 2004-05-12
EA200000969A1 (ru) 2001-06-25
KR20010042815A (ko) 2001-05-25
AU748352B2 (en) 2002-06-06
HUP0102543A3 (en) 2002-01-28
PT1073658E (pt) 2003-12-31
CA2329077A1 (fr) 1999-10-28
CN1229349C (zh) 2005-11-30
ES2242124T3 (es) 2005-11-01
PL343794A1 (en) 2001-09-10
IL138907A (en) 2007-08-19
TR200003039T2 (tr) 2001-01-22
YU63500A (sh) 2002-11-15
DE69910368D1 (de) 2003-09-18
ATE247117T1 (de) 2003-08-15
EP1371647A3 (fr) 2004-07-28
TNSN99073A1 (fr) 2005-11-10
BG104949A (en) 2001-06-29
AR057934A2 (es) 2007-12-26
SI1073658T1 (en) 2003-12-31
ATE299503T1 (de) 2005-07-15
HUP0102543A2 (hu) 2001-11-28
AU2742599A (en) 1999-11-08
US6251904B1 (en) 2001-06-26
US6458951B2 (en) 2002-10-01
IS5650A (is) 2000-09-29
EP1073658A1 (fr) 2001-02-07
RS50011B (sr) 2008-09-29
UY25484A1 (es) 1999-11-17
CN1134442C (zh) 2004-01-14
HK1064670A1 (en) 2005-02-04
TW593310B (en) 2004-06-21
HRP20000712A2 (en) 2001-06-30
JP2002512248A (ja) 2002-04-23
GT199900053A (es) 2000-10-04
DE69926154T2 (de) 2006-03-23
EP1073658B1 (fr) 2003-08-13
ES2203078T3 (es) 2004-04-01
JP2004099620A (ja) 2004-04-02
KR100449790B1 (ko) 2004-09-22
DZ2773A1 (fr) 2003-12-01
DE69910368T2 (de) 2004-03-25
WO1999054333A1 (fr) 1999-10-28
ID27036A (id) 2001-02-22
AP1022A (en) 2001-11-14
DE69926154D1 (de) 2005-08-18
CA2329077C (fr) 2007-09-18
MA26622A1 (fr) 2004-12-20
IL138907A0 (en) 2001-11-25
OA11502A (en) 2004-05-10
EP1371647A2 (fr) 2003-12-17
CN1305478A (zh) 2001-07-25
AP9901514A0 (en) 1999-06-30
US20010039271A1 (en) 2001-11-08
JP3721077B2 (ja) 2005-11-30

Similar Documents

Publication Publication Date Title
DK1073658T3 (da) Pyrazolopyrimidinon-cGMP PDE5-inhibitorer til behandling af sexualforstyrrelse
DK1223927T3 (da) Anvendelse af retigabin til behandling af neuropatiske smerter
EE200300227A (et) P38 kinaasiga seotud haigusseisundite ravimeetodid ja kinaasi inhibiitoritena kasulikud pürrolotriasiiniühendid
DK1047428T3 (da) Anvendelse af morpholinol til behandlingen af seksualforstyrrelser
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1183033T3 (da) Pyrrolotriazininhibitorer af kinaser
DK2412368T3 (da) Sammensætning til behandling af ar
DK1446122T3 (da) Anvendelse af flibanserin til behandling af uregelmæssigheder ved könsdriften
DK0966447T3 (da) Anvendelige små molekyler til behandling af betændelsessygdomme
DK1028954T3 (da) Substituerede imidazoler egnede til behandling af inflammatoriske sygdomme
DK1562932T3 (da) 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
DK2189162T3 (da) Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
DK199800837A (da) Anlæg til behandling af emner
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
DK1326628T3 (da) Kemokinmutanter til behandling af dissemineret sklerose
DK1008558T3 (da) Fremgangsmåde til behandling af organisk spildevand
DK1054868T3 (da) Substituerede pyridinoarylpiperaziner egnede til behandling af prostatahyperplasi
DK1400522T3 (da) Forbindelser til behandling af impotens
DK1390364T3 (da) Aryl-8-azabicyclo[3.2.1]octaner til behandling af depression
DK1011678T3 (da) Anvendelse af mecamylamin til behandling af nikotin-responsive neuropsykiatriske lidelser
DK1311260T3 (da) Lipaseinhibitorer til behandling af dyspepsi
DK0804199T3 (da) Anvendelse af penciclovir til behandling af postherpetisk neuralgi